The UK's healthcare angel syndicate
We screen 100s of deals.
Then back the best.
We are a syndicate of clinicians, operators, and investors who back pre-seed and seed-stage HealthTech and MedTech founders with £50k-£500k.
200+
deals screened annually
£50k-£500k
investment range
7
portfolio companies
EIS / SEIS
eligible investments
Realised exits
4 exits built over 20 years of UK technology and life sciences investing.
Our track record →Pharma and clinical experience
Our founding partner spent 34 years inside one of the world's largest pharmaceutical companies.
About the founders →Co-investment partnerships
Portfolio companies in Scotland or Wales can access £350k–£2M in match funding.
See all partners →Built and scaled startups
We help founders pressure-test scope, plans, and risk across multiple early-stage companies.
See who we are →For Investors
Healthcare investing is messy. We assess the risks before sharing a deal with you.
We check the clinical evidence, the regulatory path, the commercial model, and the team before a deal reaches members. You only see the ones that passed.
Screened deal flow
200+ deals screened annually. You see only the ones that have passed clinical, commercial, and team diligence.
EIS / SEIS tax relief
Many investments qualify for SEIS (50%) or EIS (30%) income tax relief, significantly improving your effective return profile.
Invest alongside experts
Our syndicate includes doctors, surgeons, professors, technical experts and experienced angel investors.
Hands-off or hands-on
Invest passively alongside the Pulse Angels team, or contribute your expertise directly to portfolio companies as an advisor.
New to angel investing? Read our guide for healthcare professionals.
For Founders
We invest in founders who understand the problem better than anyone else
Pulse Angels backs pre-seed and seed-stage HealthTech and MedTech companies where domain expertise is as important as the technology. We screen 200+ deals per year and invest in the ones where the product, the team, and the market opportunity line up.
Investment criteria
- Pre-seed to seed stage
- HealthTech, MedTech, or scientific platform
- Clear clinical problem with evidence of demand
- Team with domain credibility
- Realistic regulatory pathway
- Unit economics that work
Why founders choose us
Smart capital, not a crowded cap table
We bring £50k-£500k from a focused syndicate without overloading your cap table. We help with clinical validation, financial model review, and the investor story for the next round.
Clinical and commercial experience
Our team has scaled early-stage startups and navigated clinical, regulatory, and commercial challenges. We have raised venture capital and run products through NHS procurement.
Introductions that move things
Access match funding via Scottish Enterprise and the Development Bank of Wales, plus specialist regulatory and technical teams from our partner network.
In practice
How a recent investment unfolded
A representative example of how we assessed and completed a pre-seed MedTech investment. Details anonymised to protect commercial confidentiality.
Inbound via syndicate member referral. Sector fit confirmed immediately: MedTech, pre-seed, NHS-addressable condition with a documented £1bn+ annual burden. Passed to first meeting.
A 45-minute session with Simran. Unit economics stress-tested line by line. Go-to-market assumptions challenged. Key question answered: is the reimbursement pathway realistic?
Clinical evidence base reviewed against published literature. IVD regulatory route confirmed as established (not pioneering). NHS procurement framework mapped: existing procurement code identified.
Detailed briefing note issued to 19 qualified investor members. Included: clinical summary, regulatory pathway, competitive landscape, financial model, and risk register. Live Q&A session held. Clinical questions fielded by our clinical advisor network.
£200k from Pulse Angels. Four syndicate co-investors joined the round. Scottish Enterprise match funding subsequently triggered for the company's Scottish operations.
Deal snapshot
- Company type
- MedTech - non-invasive diagnostics
- Stage
- Pre-seed
- Clinical problem
- High-cost, preventable NHS condition (£1bn+ annual burden)
- Regulatory pathway
- IVD - established route, not pioneering
- Pulse Angels investment
- £200k
- Syndicate co-investors
- 4 members joined the round
- Additional funding triggered
- Scottish Enterprise match funding
- Days to term sheet
- 14
What people say
What members value in practice
“Pulse Angels brings something different. Sector knowledge that runs deep, and a network that opens doors most generalist investors can't. The diligence is thorough and the team moves quickly.”
Technology expert
Anil Jagota
Angel Investor & Syndicate Member
Member since founding - has co-invested in multiple Pulse Angels deals
“As a clinician, I was sceptical about how well an investment group would understand the realities of healthcare. Pulse Angels surprised me. The clinical due diligence is serious and the founders they back understand the pathway.”
Clinical rigour
Dr Patel
Doctor & Syndicate Advisor
Reviews clinical evidence and regulatory pathway on MedTech deals before they reach the syndicate
“The quality of deal flow and the briefings are exceptional. I've seen dozens of syndicates and Pulse Angels is the only one where I feel confident the non-financial risks have been properly assessed.”
Investor perspective
Paul Cashman
Partner
M&A expert with links to institutional investors
Common questions